Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M. Goldman

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
Haematologica|October 26, 2010
Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised hostHugues de Lavallade, Paula Garland, Takuya Sekine, et al.
Blood|August 30, 2002
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemiasOliver G Ottmann, Brian J Druker, Charles L Sawyers, et al.
Blood|October 22, 2009
Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutationFranck E Nicolini, Michael J Mauro, Giovanni Martinelli, et al.
The New England Journal of Medicine|August 16, 2002
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor betaJane F Apperley, Martine Gardembas, Junia V Melo, et al.
Blood|March 9, 2006
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsTimothy Hughes, Michael Deininger, Andreas Hochhaus, et al.
The New England Journal of Medicine|March 15, 2003
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaStephen G O'Brien, François Guilhot, Richard A Larson, et al.
Blood|August 24, 2013
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemiasChristopher J Walker, Joshua J Oaks, Ramasamy Santhanam, et al.
Blood|March 6, 2002
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyMoshe Talpaz, Richard T Silver, Brian J Druker, et al.
Blood|September 9, 2006
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disordersMarianna David, Nicholas C P Cross, Sonja Burgstaller, et al.
Blood|August 9, 2013
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignanciesJoshua J Oaks, Ramasamy Santhanam, Christopher J Walker, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
Haematologica|October 26, 2010
Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised hostHugues de Lavallade, Paula Garland, Takuya Sekine, et al.
Blood|August 30, 2002
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemiasOliver G Ottmann, Brian J Druker, Charles L Sawyers, et al.
Blood|October 22, 2009
Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutationFranck E Nicolini, Michael J Mauro, Giovanni Martinelli, et al.
The New England Journal of Medicine|August 16, 2002
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor betaJane F Apperley, Martine Gardembas, Junia V Melo, et al.
Blood|March 9, 2006
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsTimothy Hughes, Michael Deininger, Andreas Hochhaus, et al.
The New England Journal of Medicine|March 15, 2003
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaStephen G O'Brien, François Guilhot, Richard A Larson, et al.
Blood|August 24, 2013
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemiasChristopher J Walker, Joshua J Oaks, Ramasamy Santhanam, et al.
Blood|March 6, 2002
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyMoshe Talpaz, Richard T Silver, Brian J Druker, et al.
Blood|September 9, 2006
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disordersMarianna David, Nicholas C P Cross, Sonja Burgstaller, et al.
Blood|August 9, 2013
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignanciesJoshua J Oaks, Ramasamy Santhanam, Christopher J Walker, et al.
Pageof 10